Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02607657
Other study ID # GDN 055/15
Secondary ID
Status Withdrawn
Phase Phase 1
First received November 16, 2015
Last updated January 31, 2017
Start date May 2016

Study information

Verified date January 2017
Source Biolab Sanus Farmaceutica
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase I, open-label, randomized, parallel trial to evaluate the pharmacokinetics of Eplerenone tablet at different dosages (25 mg once daily, 50 mg once daily, 100 mg (2 tablets of 50 mg) once daily and 50 mg twice daily). Sample size is 96 participants (24 per treatment group), male or female, aged between 18 and 50 years-old.

Primary objective is to evaluate pharmacokinetics of Eplerenone tablet at different dosages, and secondary objective is to evaluate safety and tolerability of the investigational product.

Study overall duration is approximately 12 weeks, including enrollment and follow-up visits. Participants will be admitted for a period of 36 hours, when investigational product will be administered, and blood samples, at pre-determined time periods, will be collected for pharmacokinetics.

Primary endpoint is to obtain pharmacokinetics parameters. Additionally, safety will be assessed by adverse events occurrence and laboratory exams evaluation.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date October 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Male or female study participants, aged between 18 and 50 years-old;

- Healthiness, according to clinical, laboratory and electrocardiographic evaluations;

- Ability to understand the nature and objectives of the trial, including risks and adverse events; willingness to cooperate with the researcher and proceed according to all study requirements, which shall be confirmed by Informed Consent Form signature.

Exclusion Criteria:

- Known hypersensitivity to the investigational product (Eplerenone) or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug;

- History or presence of hepatic or gastrointestinal diseases, or other condition that interferes with drug absorption, distribution, excretion or metabolism;

- Chronic therapy with any drugs, except oral contraceptives;

- History of hepatic, kidney, lungs, gastrointestinal, epileptic, hematologic or psychiatric disease; hypotension or hypertension, of any etiology, that requires pharmacological treatment; history of myocardial infarction, angina and/or heart failure;

- Electrocardiographic findings that, at investigator criteria, are not recommended for study participation;

- Deviations on screening laboratory results that are considered clinically relevant by the researcher, preventing the subject to participate in the trial;

- Smoking;

- Intake of more that 5 cups of coffee or tea per day;

- Unusual food habits, e.g., vegetarians;

- History of drugs and alcohol addiction or excessive alcohol consumption (> 35 g/day);

- Use of regular medications within 2 weeks prior study enrollment or use of any medications within one week prior to study enrollment, except oral contraceptives or cases which, based on drug's or metabolite's half-life, complete elimination can be assumed;

- Hospitalization for any reasons up to 8 weeks before trial;

- Treatment, within 6 months before the trial, with any drugs with known and well-established toxic potential to major organs;

- Participation in any other experimental research or administration of any experimental drug within 3 months before this trial;

- Donation or loss of 450 mL or more of blood within 3 months before this trial or 3 donations (women)/4 donations (men) of blood within 12 months before this trial;

- Any condition, according to investigator's best judgement, that prevents the subject to participate in the trial;

- Pregnancy, labor or miscarriage with 12 weeks before admission predicted date.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Eplerenone 25 mg

Eplerenone 50 mg

Eplerenone 100 mg

Eplerenone 50 mg twice a day

Eplerenone 25 mg twice a day


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Biolab Sanus Farmaceutica

Outcome

Type Measure Description Time frame Safety issue
Primary Area under the curve(0-last) 24 hours
Primary Area under the curve(0-all) 24 hours
Primary Area under the curve(0-inf) 24 hours
Primary Half-life (t1/2) 24 hours
Primary Elimination rate constant (Ke) 24 hours
Primary Maximum serum concentration (Cmax) 24 hours
Primary Time to reach maximum (peak) plasma concentration following drug administration (tmax) 24 hours
Primary Time of the last measurable (positive) concentration (tlast) 24 hours
Primary Area under the first moment of the plasma concentration-time curve extrapolated from time zero to infinity as a percentage of total AUC 24 hours
Secondary Number of adverse events 30 days
Secondary Intensity of adverse events 30 days
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1